Biotech7 hours ago
Leo Pharma Grows in Spain, Driven by Sales of its Psoriasis and Atopic Dermatitis Treatments
Leo Pharma’s Spanish unit earned €97M in 2024, up 4% from 2023, led by dermatology (€61.2M, 67% of revenue). Biodermatology grew over 20%, driven by Adtralza....